While the majority of people with COVID-19 won’t require hospitalization, those who do are likely to seek medical help as a result of acute respiratory distress syndrome, or ARDS, a severe lung injury common in patients with critical illnesses. At present, there is no effective treatment for ARDS other than supportive care with mechanical ventilation.
A team of physician-scientists at Beth Israel Deaconess Medical Center (BIDMC) — part of Beth Israel Lahey Health — are now enrolling patients in a clinical trial to evaluate a common anti-clotting drug for the treatment of COVID-19-positive patients with ARDS. The newly launched trial follows a special report the team published in the Journal of Trauma and Acute Care Surgery that suggested the use of a drug called tPA could
